- Home
- MPB vs ZVRA Comparison
MPB vs ZVRA Comparison
Compare MPB & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- ZVRA
- Stock Information
- Founded
- MPB 1868
- ZVRA 2006
- Country
- MPB United States
- ZVRA United States
- Employees
- MPB N/A
- ZVRA N/A
- Industry
- MPB Major Banks
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- MPB Finance
- ZVRA Health Care
- Exchange
- MPB Nasdaq
- ZVRA Nasdaq
- Market Cap
- MPB 628.8M
- ZVRA 627.7M
- IPO Year
- MPB N/A
- ZVRA 2015
- Fundamental
- Price
- MPB $28.13
- ZVRA $9.43
- Analyst Decision
- MPB Buy
- ZVRA Strong Buy
- Analyst Count
- MPB 2
- ZVRA 10
- Target Price
- MPB $34.50
- ZVRA $22.67
- AVG Volume (30 Days)
- MPB 122.8K
- ZVRA 1.5M
- Earning Date
- MPB 07-23-2025
- ZVRA 08-12-2025
- Dividend Yield
- MPB 2.84%
- ZVRA N/A
- EPS Growth
- MPB N/A
- ZVRA N/A
- EPS
- MPB 2.30
- ZVRA N/A
- Revenue
- MPB $191,454,000.00
- ZVRA $62,020,000.00
- Revenue This Year
- MPB $24.31
- ZVRA $303.00
- Revenue Next Year
- MPB $13.74
- ZVRA $77.66
- P/E Ratio
- MPB $12.22
- ZVRA N/A
- Revenue Growth
- MPB 13.34
- ZVRA 161.81
- 52 Week Low
- MPB $22.50
- ZVRA $6.19
- 52 Week High
- MPB $33.87
- ZVRA $13.16
- Technical
- Relative Strength Index (RSI)
- MPB 52.30
- ZVRA 36.28
- Support Level
- MPB $27.10
- ZVRA $8.61
- Resistance Level
- MPB $28.85
- ZVRA $12.23
- Average True Range (ATR)
- MPB 0.54
- ZVRA 0.61
- MACD
- MPB 0.14
- ZVRA -0.33
- Stochastic Oscillator
- MPB 67.86
- ZVRA 22.53
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.